Context Therapeutics (NASDAQ:CNTX) Reports Quarterly Earnings Results

Context Therapeutics (NASDAQ:CNTX) announced its quarterly earnings results on Wednesday. The company reported earnings of ($0.22) per share (EPS) for the quarter. This figure fell short of analysts' consensus estimate of ($0.11) by a margin of ($0.11), according to reports from Zacks.

Context Therapeutics Stock Performance

On Friday, shares of Context Therapeutics traded down by 6.7%, reaching $1.95. During the trading session, 339,093 shares were exchanged, exceeding the average volume of 309,652 shares. Over the past year, the stock has seen a low of $0.77 and a high of $2.75. The company's market capitalization stands at approximately $146.25 million, with a price-to-earnings ratio of -2.14, and a beta of 2.25. The 50-day moving average price is $2.09, while the 200-day moving average price is $2.06.

Analyst Ratings

In a separate report, HC Wainwright maintained a 'buy' rating on Context Therapeutics and set a price target of $6.00 for the shares on September 23rd.

About Context Therapeutics

Context Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for treating solid tumors. The company’s lead product candidate is CTIM-76, a bispecific antibody that targets Claudin 6 (CLDN6) alongside CD3 to activate T-cells against malignant cells expressing CLDN6. They have also partnered with Integral Molecular, Inc. to develop a CLDN6 bispecific monoclonal antibody aimed at cancer therapy.

Investment Considerations

Investors considering a stake in Context Therapeutics should be aware of the company's current valuation and analyst sentiments. Although the stock has garnered a "Buy" rating among analysts, other top-rated stocks have emerged that may present better investment opportunities.

Context, Earnings, Stock